Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions
Document Type
Artefact
Department
Office of the Provost
Abstract
Background: Heart transplantation represents an increasingly utilized procedure for end-stage heart failure patients.
Current evidence: Cardiac allograft vasculopathy (CAV) is a post-transplant complication of pathological vasculature remodeling and remains an important cause for long-term graft failure and mortality. Current preventive strategies for CAV include optimization of vascular risk factors and pharmacotherapy with statins and immunosuppressants.
Conclusion: Despite demonstrated post-transplant mortality benefit and reduction in CAV with statins, the role of other pharmacotherapies on CAV reduction through low-density lipoprotein cholesterol (LDL-C) lowering remains less established. This review explores established evidence as well as evolving pathways for LDL-C lowering strategies to prevent CAV.
Publication (Name of Journal)
Journal of Clinical Lipidology
DOI
10.1016/j.jacl.2025.12.001
Recommended Citation
Mansoor, T.,
Ismayl, M.,
Virani, S. S.,
Nambi, V.,
Misra, A.,
Jia, X.,
Fudim, M.,
Sperling, L.,
Parikh, S.,
Rifai, M. A.
(2026). Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. Journal of Clinical Lipidology, 20(2), 262-269.
Available at:
https://ecommons.aku.edu/provost_office/858